Assessment of Physical Effort in People With Newly Diagnosed Type 1 Diabetes Mellitus and Its Impact on: Partial Clinical Remission, Insulin Resistance, HDL Cholesterol Function, Immune Function and Length of Life.

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The Diab1Fit Study project aims to a multidirectional assessment of physical activity and its impact in people with type 1 diabetes (DM1). To the study are recruited people with newly diagnosed DM1, treated with intensive functional insulin therapy from the beginning of the disease. The study is planned to cover a minimum of 100 people with newly diagnosed DM1 and lead prospective observation of this group (for a minimum of 5-10 years). The investigators will evaluate the effect of VO2max in people with newly diagnosed DM1 on partial clinical remission. What is more the investigators also assess quantitative and qualitative changes of plasma lipoproteins, with particular emphasis on HDL metabolism, mechanism linking VO2max with management of DM1 (longevity proteins, miostatin, insulin resistance) and immune function.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 35
Healthy Volunteers: f
View:

• Age 18-35 years,

• New onset type 1 diabetes (confirmed by the presence of antibodies - antyGAD, ICA, IA2)

• Treatment with intensive insulin therapy,

• Written consent to participate in the study.

Locations
Other Locations
Poland
Department of Internal Medicine and Diabetiology Poznan University of Medical Sciences
RECRUITING
Poznan
Time Frame
Start Date: 2020-01-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 100
Treatments
People with newly diagnosed diabetes mellitus type 1
People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology.~Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
Related Therapeutic Areas
Sponsors
Leads: Poznan University of Medical Sciences

This content was sourced from clinicaltrials.gov